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The timing of the attachment of fatty acids to the hemagglutinin (HA) of influenza A virus was studied. Treatment of virus infected cells with 
brefeldin A (BFA), a drug which blocks intracellular transport along the exocytic pathway at a pre-Go&i site, does not prevent pahnitoylation 
of HA. The relationship of HA-palmitoylation to the oligomerisation and to the proteolytical cleavage of the protein revealed that the uncleaved 
trimer of HA is the substrate for the acylating enzyme in virus infected cells. The results are discussed with regard to the intracellular site of 
palmitoylation. 
Influenza virus; Hemagglutinin; Intracellular transport; Palmitoylation; Oligomerisation; Brefeldin A 
1. INTRODUCTION 
The hemagglutinin of intluenza virus is a typical type 
I membrane glycoprotein with a large N-terminal ecto- 
domain, one membrane spanning region and a short 
cytoplasmic tail. Besides its important role for virus 
infectivity [l], HA is a model system for glycoproteins 
in general, because its structure, biosynthesis and 
posttranslational modifications have been studied in 
great detail [2]. The polypeptide chain is synthesized on 
membrane-bound ribosomes and translocated into the 
lumen of the endoplasmic reticulum (ER), where signal- 
peptide cleavage, N-linked glycosylation, folding and 
disulfide-bond formation occur. Post-translationally 
but still in the ER, three HA molecules assemble to a 
trimer [3-51. Subsequent o its transport through the 
recently described intermediate compartment or cis- 
Golgi network (CGN) [6], trimming of HA-linked car- 
bohydrates occurs in medial-Go& vesicles and terminal 
glycosylation in the trans-Golgi network (TGN). Also 
in the TGN HA is cleaved into the membrane-spanning 
HA2 and the large N-terminal HA, subunits by the 
cellular endoprotease furin [7]. HA is then transported 
to the plasma membrane and incorporated into virus 
particles during the budding process. Half-times of 7-10 
min for oligomerisation [3,4], of 15-20 min for carbohy- 
drate processing and proteolytical cleavage, and of 60 
min between translation and exposure at the cell surface 
have been reported [8]. 
is not known. Results in this respect have been reported 
only for other viral acylproteins. Using pulse-chase x- 
periments on toga- or rhabdovirus infected cells, it was 
shown, that pahnitoylation occurs posttranslationally 
before the carbohydrate-chains of the respective 
glycoprotein are trimmed and before proteolytical 
cleavage of the precursor proteins [12]. From subcellu- 
lar fractionation studies it has been suggested that 
pahnitoylation occurs either in the cis-Golgi cisternae or 
in the endoplasmic reticulum [13-151. Using low tem- 
perature (15°C) to block transport of proteins along the 
exocytotic pathway at a pre-Golgi site and temperature- 
sensitive transport mutants of viral acylproteins, pahni- 
toylation was located to a post ER/pre-Golgi compart- 
ment [16,17]. However, a number of cellular acylpro- 
teins are palmitoylated also at the plasma membrane, 
and their fatty acids are apparently subject to cycles of 
de- and reacylation [18-201. 
Here we have studied the timing of pahnitoylation of 
influenza A virus HA by two novel approaches. Intra- 
cellular transport of HA was blocked at a pre Go&site 
using the fungal metabolite brefeldin A [21]. The tempo- 
ral relation of pahnitoylation and oligomerisation of 
HA was studied using short-pulse labeling and sucrose- 
gradient centrifugation. This is of considerable interest, 
because oligomerisation is also believed to occur at in- 
tracellular sites considered above for palmitoylation [5]. 
Another posttranslational modification of HA is the 
attachment of fatty acids, mainly pahnitic acid, to three 
conserved cysteine residues in the cytoplasmic tail of the 
molecule [9-l 11. The timing of HA pahnitoylation rela- 
tive to the other above-mentioned protein modifications 
2. MATERIALS AND METHODS 
2.1. virus infection, metabolic labeling 
*Corresponding author. Fax: (49) (30) 4547-2328. 
Confluent chicken embryo fibroblasts (CEF) were infected with 
influenza A virus (A/FPV/RostocW34 [H7,Nl], fowl plague virus) at 
a multiplicity of infection of 50. Four hours after infection the cells 
were labeled with [%]methionine (lOO~Ci/ml Dulbecco medium with- 
out methionine, 1000 Ci/mmol, Amersham) or [3H]palmitic acid (1 
mCi/ml Dulbecco medium, 54 Wmmol, Amersham) for the times 
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indicated in the text. For pulse-chase xperiments with [35S]methionine 
the chase was initiated by the addition of unlabeled methionine to a 
final concentration of 10 mM. At the end of the chase the cell mono- 
layers were washed on ice with phosphate-buffered saline and subse- 
quently lysed with RIPA-buffer [lo] or T&on-lysis buffer (1% Triton 
X-100,20 mM MES, 30 mM Tris, 100 mM NaCl, 40 mM EDTA, 10 
mM iodoacetamide, 1mM PMSF, 5% Trasylol). HA was immunopre- 
cipitated with a polyclonal rabbit serum against fowl plague virus or 
the monoclonal antibody He-2 [31] and subjected to SDS-PAGE and 
tluorography as described previously [lo]. 
2.2. Cycloheximide and brefeldin A treatment 
Influenza virus infected monolayers were treated with cyclo- 
heximide (Sigma, Deisenhofen, Germany; 50 &ml final concentra- 
tion) or BFA (Epicentre technologies, Madison, WI, USA; 6 pg/ml) 
at the times indicated in the text before metabolic labeling. Both 
inhibitors were also present hroughout he labeling and chase periods. 
Stock solutions of BFA (10 mg/ml methanol) and cycloheximide (50 
mg/ml ethanol) were stored at -20°C. 
2.3. Sucrose-gradient centrifugation 
Virus-infected cells were lysed with Triton-lysis buffer. Cleared ly- 
sates (100,000 x g for 30 min) were layered onto a linear sucrose 
gradient (5% to 20% sucrose in 100 mM NaCI, 20 mM ME& 30 mM 
Tris, 10 mM CaCl,, 1% Triton X-100) and monomers and trimers of 
HA separated by centrifugation at 40,000 rpm for 16 h at 4°C in a SW 
41 rotor (Beckman). The material was fractionated from the bottom 
of the tube to lml per fraction. Each fraction was diluted 1:4 with 
RIPA- buffer and HA was immunoprecipitated. 
3. RESULTS 
To relate pahnitoylation to the proteolytical cleavage 
of HA, influenza A virus infected chicken embryo fi- 
broblasts (CEF) were pulse-chase labeled with 
[3H]palmitic acid. HA was immunoprecipitated from 
cell extracts and subjected to SDS-PAGE and fluoro- 
graphy. As seen from the results shown in Fig. lA, 
freshly acylated, pulse-labeled HA is uncleaved (lane 1) 
and Endo-H digestion revealed that it has not under- 
gone trimming of its carbohydrate side chains (not 
shown). After 15 min of chase approximately 60% of 
[3H]palmitic acid labeled HA is cIeaved (Fig. lA, lane 
2) and proteolytic processing of HA is complete after 
about one hour of chase (lane 3). No loss of [3H]palmitic 
acid label was detectable during the chase periods, 
which indicates that the fatty acids are stably attached 
to the viral glycoprotein during its transport to the 
plasma membrane and thus no substrate for deacyla- 
tion. 
To examine the dependence of palmitoylation on on- 
going protein synthesis, polypeptide translation in influ- 
enza virus infected cells was blocked by the addition of 
cycloheximide. Cells were then labeled for 10 min at 0, 
5, 10 or 15 min after adding cycloheximide. Fig. 1B 
(lanes 1 and 2) shows that [3H]palmitic acid labeling of 
HA decreases continually until 10 min after cyclo- 
heximide addition and is virtually absent 15 (lane 4) and 
60 (not shown) min after the block in protein synthesis. 
This indicates, that palmitoylation of HA is a post- 
translational, but relatively early event in the matura- 
tion of the protein. 
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Fig. 1. Pahnitoylation of HA occurs before its proteolytical cleavage. 
(A) CEF cells infected with influenza A virus were labeled for 5 min 
with rH]palmitic acid and chased for 0 min (lane l), 15 min (lane 2) 
or 60 min (lane 3). HA was immunoprecipitated with influenza virus 
antiserum and subjected to SDS-PAGE and fluorography. (B) Influ- 
enza virus infected CEF cells were treated with cycloheximide (50 
@ml) and labeled simultaneously (lane 1) or 5 min (lane 2), 10 min 
(lane 3) and 15 min (lane 4) after adding the drug each for 10 min with 
[‘Hlpalmitic acid. HA was immunoprecipitated and subjected to SDS- 
PAGE and fluorography. 
To pinpoint the intracellular site of HA-palmitoyla- 
tion more closely, intracellular transport of HA was 
blocked at a pre-Golgi site using the fungal metabolite 
brefeldin A (BFA). Because cell-type and species-spe- 
cific differences in the action of the drug have been 
reported [21], we firstly determined whether BFA inhib- 
its transport in our system using the cleavage of HA as 
a marker, since this event depends on transport. Influ- 
enza A virus infected chicken embryo fibroblasts were 
treated with BFA one hour before pulse-chase labeling 
with [35S]methionine. Immunoprecipitation of influenza 
virus specific proteins revealed, that pulse-labeled HA 
is uncleaved in BFA-treated and untreated cells (Fig. 
2A, lanes 1 and 2). Due to the proteolytical processing, 
uncleaved HA is no longer detectable in untreated cells 
after a chase of one hour (Fig. 2A, lane 3) but prevails 
in large amounts in BFA-treated cells (lane 4). This 
control experiment shows that BFA indeed inhibits ex- 
ocytotic transport in our cell system (CEF). 
Labeling with [3H]palmitic acid in the presence of the 
drug revealed that BFA has no effect on palmitoylation 
of HA (Fig. 2B). Because BFA is known to cause disin- 
tegration of Golgi-vesicles thereby leaving the CGN 
and the ER intact [22], these results support a pre- 
Golgi-site for palmitoylation of HA. 
Next we defined the temporal relation between palmi- 
toylation and oligomerisation of HA, a modification 
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Fig. 2. BFA treatment does not abolish pahnitoylation of HA. (A) 
Influenza virus infected CEF were left untreated (lanes 1 and 3) or 
were treated with brefeldin A (lanes 2 and 4). Cells were labeled 1 h 
later with [35S]methionine for 10 min and chased for 0 min (lanes 1 and 
2) or 60 min (3 and 4). Influenza virus specific proteins were im- 
munoprecipitated from cell extracts and subjected to SDS-PAGE and 
fluorography. HA cleavage products HA, and HA, are not separated 
from the other viral proteins NP and M, respectively. (B) Infected 
CEF were labeled with [3H]palmitic acid for 10 min in the presence 
(lane 1) or absence (lane 2) of BFA. The drug was added at 6 pg/ml 
final concentration 1 h before labeling. Lane 3 = uninfected control 
cells. 
which is believed to occur in the ER just before the 
newly translated protein leaves this compartment [3- 
5,231. To follow trimerization of HA experimentally, 
influenza A virus infected chicken embryo fibroblasts 
(CEF) were pulse-chase labeled with [35S]methionine. 
Cells were lysed in non-ionic detergent and monomers 
and trimers were separated by sucrose-gradient centrif- 
ugation and fractionation of the gradient. Immunopre- 
cipitation, SDS-PAGE and fluorography revealed that 
after short-pulse labeling with [35S]methionine HA 
bands appear in fractions 4-6 of the gradient, which 
represents the monomeric form of the molecule (Fig. 
3A). As shown in Fig. 3B, HA is closer to the bottom 
of the gradient after a 15 min chase period (fractions 
l-3), which is the position of the trimer and cleavage of 
the protein to HA, and HA, has begun. This is in agree- 
ment with previous studies on the kinetics of HA-oli- 
gomerisation [3,4]. However, after short-pulse labeling 
with [3H]palmitic acid HA bands to fractions l-3 and 
is thus completely trimerized (Fig. 3C). As shown in the 
same figure this material is still uncleaved, which indi- 
cates that palmitoylation occurs after oligomerisation 
of HA, but before its cleavage to HA, and HA,. Results 
from cross-linking experiments with dimethylsuberimi- 
dat (DMS) also reveal trimerization of HA before 
palmitoylation (not shown) which supports our inter- 
pretation, that the uncleaved trimer of HA serves as the 
substrate for the palmitoylating enzyme in influenza 
virus-infected cells. 
4. DISCUSSION 
We describe here the timing of fatty acid attachment 
to the influenza virus hemagglutinin in relation to some 
other well-established modifications of this protein. 
Short-pulse [3H]palmitic acid labeled and therefore 
freshly acylated HA is completely trimerized (Fig. 3C), 
but has not undergone proteolytical cleavage (Figs. 1 
and 3) or trimming of its N-linked carbohydrates. This 
would suggest hat trimerization and palmitoylation are 
not only sequential events but that they occur in differ- 
ent intracellular compartments. Our results further ex- 
clude a possible involvement of HA-bound fatty acids 
in the initiation of oligomerization. 
This interpretation is in agreement with similar con- 
clusions from published results using a different ap- 
proach. In these studies acylation of Semliki-Forest 
virus (SFV) E-proteins and vesicular stomatitis virus 
(VSV) G-protein was blocked at 15°C [17], whereas 
oligomerisation was not affected [5,23]. 
Continuous acylation of HA is a posttranslational 
event which depends on ongoing protein-synthesis since 
a loss of [3H]pahnitic acid label of the hemagglutinin 








Fig. 3. Pahnitoylation of HA occurs after its trimerization. CEF in- 
fected with influenza virus were labeled with [35S]methionine (panels 
A and B) or [‘Hlpalmitic acid (C) for 3 min. Cells were lysed with 
non-denaturing detergent immediately (panels A and C) or after a 
chase period of 15 min (B). Cleared cell extracts were centrifuged in 
a Z-208 sucrose gradient containing 1% Triton X-100 at 40,000 rpm 
for 16 h. The gradient was fractionated and HA immunoprecipitated 
from every fraction with the monoclonal antibody HC-2 and subjected 
to SDS-PAGE and fluorography. Fraction 1 represents the bottom, 
fraction 11 the top of the gradient. 
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This indicates, that the fatty acids are stably attached 
to the viral glycoprotein and are not subject to cycles of 
deacylation and reacylation. This is in agreement with 
our earlier studies on the palmitoylation of Sindbis and 
VSV glycoproteins [12]. However, ‘turn-over’ of ester- 
linked fatty acids has been described for several cellular 
acylproteins, notably the transferrin-receptor, the ras- 
protein and ankyrin [18-201. The reason for this differ- 
ence between viral and cellular acylproteins, which are 
both acylated at cysteine residues [24] is not known. The 
viral proteins may escape action of the acylesterase, 
because they leave the host cell into budding virus par- 
ticles. The alternative possibility that cellular acylpro- 
teins may have specific structural features, which are 
recognized by the acylesterase and which are not pres- 
ent in viral acylproteins seems unlikely, because cleav- 
age of thioester-linked fatty acids has been described for 
the E2 protein of Semliki-Forest virus in a cell-free sys- 
tem [25]. 
Blocking intracellular transport at a pre-Golgi site 
with brefeldin A (BFA) does not abolish palmitoylation 
of HA (Fig. 2). This is in accordance with studies on two 
cellular acylproteins (~62 and p63), where BFA-treat- 
ment even causes an enhancement of palmitoylation 
[26,27]. 
Based on the evidence that (i) trimerization of HA is 
completed in the ER [3-5,231, (ii) HA leaves this com- 
partment rapidly after its oligomerisation [3-5,231, and 
(iii) BFA treatment allows proteins to reach the CGN 
[21,22], our results show that palmitoylation of HA lo- 
calizes to the CGN. This supports similar conclusions 
by others who related the timing of palmitoylation and 
oligosaccharide processing [ 16,171. Furthermore, one 
particular palmitoylated protein (~63) could be located 
exclusively to the CGN [27]. The differing data on the 
location of freshly acylated proteins are based soley on 
cell fractionation methods [13-151 and may be due to 
the possibility that the CGN co-purifies with the ER in 
one experimental system, but to the Golgi-cisternae in 
an other. 
However, it cannot be excluded at present that the 
protein-acyltransferase (PAT) is present at multiple in- 
tracellular sites besides the CGN. Several observations 
point to this possibility. Vesicle-mediated in vitro trans- 
port of glycoproteins between all the various Golgi cis- 
ternae depends on the presence of activated fatty acids 
[28,29]. The authors speculate that cycles of acylation 
and deacylation of an unknown cellular protein are re- 
quired for budding, targeting and fusion of transport 
vesicles. This assumption would imply that acylating 
enzymes are located at all these different intracellular 
sites. Recently palmitoylating activity was detected in 
extracts from ghosts prepared from human red blood 
cells (Schmidt, Burns and Mcllhinney, unpublished re- 
sults). Furthermore, palmitoylation of the mature form 
of several cellular membrane proteins has been reported 
[18,24], suggesting that PAT is also present at the 
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plasma membrane. Palmitoylating enzymes located dis- 
tally to the CGN are not active on viral glycoproteins, 
probably because all potential acylation sites are filled 
during the first encounter with an acylating enzyme and 
because the fatty acids are stably attached to the viral 
glycoprotein. Definite proof for any of these hypotheses 
requires biochemical purification of PAT [30] and the 
examination of its intracellular location with immuno- 
logical methods. This would also help clarify whether 
we are dealing with one PAT or with a number of 
acylating enzymes with similar properties. 
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